Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. [PDF]
Antimicrob Agents ChemotherMohammad S +4 more
europepmc +1 more source
Current progress in antibacterial agents for carbapenem-resistant enterobacterales. [PDF]
Front PharmacolXu W +10 more
europepmc +1 more source
In vivo pharmacokinetic analysis of meropenem/vaborbactam during continuous venovenous haemodialysis
Journal of Antimicrobial Chemotherapy, 2019 Wesley D Kufel +5 more
openaire +2 more sources
From bugs to bots: learning infectious diseases in the AI era. [PDF]
Antimicrob Steward Healthc EpidemiolRodriguez-Nava G.
europepmc +1 more source
Characterisation of β-lactam/Vaborbactam activity in Klebsiella pneumoniae [PDF]
, 2019 Douglas, Ed J A
core
Targeting carbapenem-resistant and hypervirulent Klebsiella pneumoniae: in vitro evaluation of cefepime/zidebactam, aztreonam/avibactam, imipenem/relebactam, and meropenem/vaborbactam. [PDF]
BMC Infect DisLi Y, Li Y, Jia X, Mao H, Li D, Zhang J.
europepmc +1 more source
TDM-guided meropenem/vaborbactam-based therapy for successful treatment of intra-abdominal and bloodstream infection caused by KPC-producing ceftazidime/avibactam-resistant Klebsiella pneumoniae in a paediatric liver transplant recipient. [PDF]
J Antimicrob ChemotherMulé G +8 more
europepmc +1 more source
Classification and applicability of new beta-lactamase inhibitors. [PDF]
Rev Esp QuimioterCercenado E, Candel FJ.
europepmc +1 more source
The shift from "MIC-Only" back to carbapenemase testing among carbapenem-resistant Enterobacterales: what clinical laboratories need to know about updated CLSI guidance. [PDF]
J Clin MicrobiolSimner PJ.
europepmc +1 more source
Molecular and pharmacodynamic insights into β-lactam therapy for high-inoculum Enterobacter cloacae complex infections. [PDF]
Antimicrob Agents ChemotherKunz Coyne AJ +6 more
europepmc +1 more source